After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into the third and final
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into day 2 of the oncolo
AstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Tagrisso delays the recurrence of EGFR-positive non-smal
Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting begins at 8am (ET).